Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone Biologics (NASDAQ: TSBX) presented preclinical data on their Selected TIL technology at the 2024 SITC Annual Meeting. The research focuses on selectively expanding tumor-reactive T cells for solid tumor treatment. Two key studies were presented: one demonstrating successful TIL expansion from gastric tumors and enhancement of adoptive cell therapy, and another revealing a potential biomarker method to predict tumor-reactive T cell expansion success. The findings support the continued clinical development of TIDAL-01, currently in Phase 1 trials, and suggest that reactive TIL enrichment protocols could improve solid tumor treatment outcomes.
Turnstone Biologics (NASDAQ: TSBX) ha presentato dati preclinici sulla loro tecnologia Selected TIL durante il 2024 SITC Annual Meeting. La ricerca si concentra sull'espansione selettiva delle cellule T reattive ai tumori per il trattamento dei tumori solidi. Sono stati presentati due studi chiave: uno che dimostra l'espansione riuscita delle TIL da tumori gastrici e un miglioramento della terapia cellulare adottiva, e un altro che rivela un potenziale metodo biomarker per prevedere il successo dell'espansione delle cellule T reattive ai tumori. I risultati supportano lo sviluppo clinico continuo di TIDAL-01, attualmente in fase 1 di sperimentazione, e suggeriscono che i protocolli di arricchimento delle TIL reattive potrebbero migliorare i risultati del trattamento dei tumori solidi.
Turnstone Biologics (NASDAQ: TSBX) presentó datos preclínicos sobre su tecnología Selected TIL en la Reunión Anual SITC 2024. La investigación se centra en expandir selectivamente las células T reactivas a tumores para el tratamiento de tumores sólidos. Se presentaron dos estudios clave: uno que demuestra la expansión exitosa de TIL a partir de tumores gástricos y la mejora de la terapia celular adoptiva, y otro que revela un posible método de biomarcador para predecir el éxito de la expansión de las células T reactivas a tumores. Los hallazgos respaldan el desarrollo clínico continuo de TIDAL-01, actualmente en ensayos de fase 1, y sugieren que los protocolos de enriquecimiento de TIL reactivas podrían mejorar los resultados del tratamiento de tumores sólidos.
Turnstone Biologics (NASDAQ: TSBX)는 2024 SITC 연례 회의에서 그들의 Selected TIL 기술에 대한 전임상 데이터를 발표했습니다. 이 연구는 고형 종양 치료를 위해 종양 반응 세포 T의 선택적 확장을 중심으로 진행됩니다. 두 가지 주요 연구가 발표되었는데, 하나는 위 종양에서 성공적인 TIL 확장을 보여주고, 세포 치료를 개선하는 것이며, 다른 하나는 종양 반응 세포 T의 확장 성공을 예측하기 위한 잠재적인 바이오마커 방법을 제시합니다. 이러한 발견은 현재 1상 시험 중인 TIDAL-01의 지속적인 임상 개발을 지원하며, 반응성 TIL 농축 프로토콜이 고형 종양 치료 결과를 개선할 수 있음을 제안합니다.
Turnstone Biologics (NASDAQ: TSBX) a présenté des données précliniques sur sa technologie Selected TIL lors de la réunion annuelle SITC 2024. La recherche se concentre sur l'expansion sélective des cellules T réactives aux tumeurs pour le traitement des tumeurs solides. Deux études clés ont été présentées : l'une démontrant l'expansion réussie des TIL à partir de tumeurs gastriques et l'amélioration de la thérapie cellulaires adoptées, l'autre révélant une méthode potentielle de biomarqueur pour prédire le succès de l'expansion des cellules T réactives aux tumeurs. Les résultats soutiennent le développement clinique continu de TIDAL-01, actuellement en phase 1 d'essai, et suggèrent que les protocoles d'enrichissement des TIL réactives pourraient améliorer les résultats du traitement des tumeurs solides.
Turnstone Biologics (NASDAQ: TSBX) präsentierte auf dem 2024 SITC-Jahrestreffen präklinische Daten zu ihrer Selected TIL-Technologie. Die Forschung konzentriert sich auf die selektive Erweiterung von tumorreaktiven T-Zellen zur Behandlung solider Tumoren. Es wurden zwei wichtige Studien vorgestellt: eine, die eine erfolgreiche TIL-Erweiterung aus Magenwursttümpfen zeigt und die adoptive Zelltherapie verbessert, sowie eine andere, die eine potenzielle Biomarker-Methode zur Vorhersage des Erfolgs der tumorreaktiven T-Zell-Erweiterung aufzeigt. Die Ergebnisse unterstützen die fortgesetzte klinische Entwicklung von TIDAL-01, das sich derzeit in Phase-1-Studien befindet, und deuten darauf hin, dass reaktive TIL-Anreicherung Protokolle die Behandlungsergebnisse bei soliden Tumoren verbessern könnten.
- Successful demonstration of TIL expansion from gastric tumors
- Development of potential biomarker method for predicting treatment success
- Maintained reactivity of enriched TILs following expansion
- None.
Insights
The preclinical data presented reveals important progress in Turnstone's Selected TIL technology, particularly in two key areas: neoantigen-reactive TIL enrichment in gastric cancer and identification of biomarkers for TIL expansion prediction. The research demonstrates successful TIL expansion from gastric tumors and maintenance of reactivity after expansion - a important technical achievement for potential therapeutic applications.
The novel TCR overlap analysis between blood and tumor samples could serve as a predictive tool for patient selection, potentially improving manufacturing success rates and treatment outcomes. However, these are still preclinical findings that require validation in clinical settings. The technology's commercial viability will depend on manufacturing scalability and consistent demonstration of enhanced tumor-reactive T cell populations compared to traditional TIL approaches.
Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors
Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas.
“We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broader range of solid tumors,” said David Stojdl, Ph.D., Turnstone’s Senior Vice President of Research. “At Turnstone, we are working relentlessly to expand the frontiers for TIL therapy by developing next-generation Selected TILs aimed at harnessing a greater reactive T cell population for more potent tumor killing. We look forward to sharing new preclinical results at SITC, which build on previous findings for TIDAL-01 and from within the field, highlighting the practicality of selecting and expanding tumor-reactive TIL as a potential treatment option for patients with critical unmet needs.”
Key findings from the two poster presentations follow, copies of which will be added to Turnstone’s website and can be accessed here.
Title: Enrichment of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes (TIL) in Gastric Cancer
Date and Time: Saturday, November 9, 2024, 9:00am - 8:30pm CST
Abstract Number: 460
In collaboration with H. Lee Moffitt Cancer Center (Moffitt)
- Turnstone’s Selected TIL clinical candidate, TIDAL-01, utilizes a novel unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of the most potent tumor-reactive (neoantigen-reactive) TIL from the patient’s tumor in vitro, before infusing them into the patient for more targeted tumor killing.
- This study utilized a scaled-down research model of clinical TIL isolation and demonstrated successful TIL expansion from gastric tumors. Additionally, the use of tumor-specific neoantigens allowed the enrichment of TIL, which maintained reactivity following expansion. These results demonstrate that reactive TIL enrichment protocols may enhance adoptive cell therapy with TIL for solid tumors.
Title: Overlap Between Circulating and Intratumoral T Cell Repertoire as a Predictor of Neoantigen-Reactive TIL Ex-Vivo Expansion
Date and Time: Friday, November 8, 2024, 9:00am - 8:30pm CST
Abstract Number: 443
In collaboration with the University of Montreal Hospital Research Centre (CRCHUM)
- Although tumor-reactive TIL infused to patients are associated with clinical responses, there are currently no biomarkers that can predict whether tumor-reactive T cells can be expanded from a tumor.
- Using single T cell sequencing, this poster illustrates a manufacturing method tested to enrich TIL in tumor-reactive T cells, the results for which suggest that the degree of baseline TCR (T cell repertoire) overlap between blood and tumor repertoire could help identify patients from which tumor-reactive TIL can be expanded.
About Turnstone
Turnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Turnstone’s next-generation TIL therapy is based upon the identification, selection and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone’s clinical program, TIDAL-01, is currently being evaluated in multiple Phase 1 studies in patients with colorectal cancer, head and neck cancer, and uveal melanoma. For additional information about Turnstone, please visit www.turnstonebio.com, and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the therapeutic potential for TIDAL-01; the potential for extended clinical applications of TILs across a range of solid tumors; the ability of TIDAL-01 to utilize a screening process to isolate and selectively expand the greatest breadth of the most potent tumor-reactive TIL; the potential for TIDAL-01 to be superior to current standard of care, if approved; and Turnstone’s strategies and objectives. All statements, other than statements of historical fact, contained in this press release, including statements regarding future events, future financial performance, business strategy and plans, and objectives for future operations, are forward-looking statements and can be identifies by terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or “would,” or the negative of these terms or other comparable terminology. These statements are based on the current plans, objectives, estimates, expectations and intentions, beliefs and assumptions of our management team, and on information currently available to such management team and are not guarantees of future performance and inherently involve numerous risks and uncertainties, many of which are beyond Turnstone’s control. We undertake no obligation to update or revise publicly any of the forward-looking statements after the date hereof to conform the statements to actual results or changed expectations except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: macroeconomic conditions and the effects of global health concerns, such as global pandemics; Turnstone’s ability to initiate and execute clinical trials on the anticipated timelines, if at all; the potential for results from clinical trials to differ from preclinical, early clinical, initial, preliminary or expected results; the significant uncertainty associated with Turnstone’s product candidates ever receiving any regulatory approvals; Turnstone’s ability to obtain, maintain or protect intellectual property rights related to its product candidates; impediments to the Company’s ability to execute the workforce reduction as currently contemplated, the Company’s ability to achieve projected cost savings in connection with the workforce reduction, unintended consequences from the workforce reduction that impact the Company’s business; the sufficiency of Turnstone’s capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading “Risk Factors” in Turnstone’s Annual Report on Form 10-K or Quarterly Reports on Form 10-Q filed with the SEC and other documents Turnstone has filed, or will file, with the SEC. This press release discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the uses for which they are being studied.
Contact
Ahmed Aneizi
Investor Relations
Turnstone Biologics
(347) 897-5988
ahmed.aneizi@turnstonebio.com
FAQ
What are the key findings from Turnstone Biologics' (TSBX) SITC 2024 presentation?
What is the current development stage of Turnstone Biologics' (TSBX) TIDAL-01?
What technology is Turnstone Biologics (TSBX) developing for cancer treatment?
